Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
- Conditions
- Hyperparathyroidism, SecondaryVitamin D DeficiencyChronic Kidney Disease
- Interventions
- Other: Sugar pill to CTAP101 30 μg capsulesDrug: CTAP101 30 μg capsules
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- OPKO IP Holdings II, Inc.
- Target Recruit Count
- 216
- Registration Number
- NCT01704079
- Locations
- 🇺🇸
OPKO Renal, Bannockburn, Illinois, United States
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
- Conditions
- Hyperparathyroidism, SecondaryVitamin D DeficiencyChronic Kidney Disease
- Interventions
- Drug: CTAP101 30 μg capsulesOther: Sugar pill to CTAP101 30 μg capsules
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- OPKO IP Holdings II, Inc.
- Target Recruit Count
- 213
- Registration Number
- NCT01651000
- Locations
- 🇺🇸
OPKO Renal, Bannockburn, Illinois, United States
Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects
- Conditions
- Chronic Renal InsufficiencyChronic Renal FailureChronic Kidney DiseaseSecondary Hyperparathyroidism
- Interventions
- Drug: CTAP101 CapsulesDrug: CTAP101 Injection
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- OPKO IP Holdings II, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT00888069
- Locations
- 🇺🇸
Pivotal Research Centers, Peoria, Arizona, United States
🇺🇸Research by Design, Evergreen Park, Illinois, United States
🇺🇸Western New England Renal & Transplant Associates, Springfield, Massachusetts, United States
Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
- Conditions
- Chronic Kidney DiseaseSecondary HyperparathyroidismChronic Renal FailureChronic Renal Insufficiency
- Interventions
- Drug: CTAP201 Injection
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- OPKO IP Holdings II, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00792857
- Locations
- 🇺🇸
Pivotal Reseach Centers, Peoria, Arizona, United States
🇺🇸Western New England Renal and Transplant Associates, Springfield, Massachusetts, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
- Conditions
- Chronic Kidney DiseaseSecondary HyperparathyroidismChronic Renal InsufficiencyChronic Renal Failure
- Interventions
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2014-11-06
- Lead Sponsor
- OPKO IP Holdings II, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT00742716
- Locations
- 🇺🇸
Pines Clinical Research, Inc., Pembroke Pines, Florida, United States
🇺🇸Boise Kidney and Hypertension Institute, Meridian, Idaho, United States
🇺🇸Western New England Renal & Transplant Associates (WNERTA), Springfield, Massachusetts, United States